Drug Approval | May 23, 2023
Shilpa Medicare Analytical Services Division gets VAI status from USFDA after GMP inspection
This is the second US FDA GMP inspection of this facility within one year
This is the second US FDA GMP inspection of this facility within one year
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
India’s efforts are aimed at boosting health at the last mile
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in their respective categories as on March 2023
8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
These initiatives aim to improve access to healthcare for rare disease patients
Subscribe To Our Newsletter & Stay Updated
